Zacks: Analysts Expect MEDNAX, Inc. (NYSE:MD) to Announce $0.48 EPS

Analysts forecast that MEDNAX, Inc. (NYSE:MDGet Rating) will post $0.48 earnings per share for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for MEDNAX’s earnings, with the highest EPS estimate coming in at $0.50 and the lowest estimate coming in at $0.44. MEDNAX reported earnings of $0.41 per share during the same quarter last year, which indicates a positive year over year growth rate of 17.1%. The business is expected to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that MEDNAX will report full year earnings of $1.81 per share for the current fiscal year, with EPS estimates ranging from $1.29 to $1.98. For the next financial year, analysts expect that the company will report earnings of $2.01 per share, with EPS estimates ranging from $1.75 to $2.10. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow MEDNAX.

MEDNAX (NYSE:MDGet Rating) last announced its quarterly earnings results on Thursday, April 28th. The company reported $0.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.06. MEDNAX had a return on equity of 15.64% and a net margin of 4.73%. The company had revenue of $482.20 million during the quarter, compared to the consensus estimate of $471.29 million. During the same period in the previous year, the company posted $0.20 earnings per share. MEDNAX’s revenue for the quarter was up 7.9% on a year-over-year basis.

A number of research firms have recently commented on MD. Mizuho cut their price objective on MEDNAX from $28.00 to $23.00 in a research report on Monday, May 2nd. StockNews.com cut MEDNAX from a “buy” rating to a “hold” rating in a research report on Monday, May 2nd. TheStreet cut MEDNAX from a “b-” rating to a “c+” rating in a research report on Wednesday, April 13th. Zacks Investment Research cut MEDNAX from a “buy” rating to a “hold” rating and set a $25.00 price objective for the company. in a research report on Wednesday, April 20th. Finally, Credit Suisse Group cut their price objective on MEDNAX from $32.00 to $31.00 and set an “outperform” rating for the company in a research report on Wednesday, February 23rd. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $28.25.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Foundry Partners LLC boosted its stake in MEDNAX by 17.0% during the fourth quarter. Foundry Partners LLC now owns 460,403 shares of the company’s stock worth $12,528,000 after buying an additional 66,916 shares during the last quarter. Yousif Capital Management LLC acquired a new position in shares of MEDNAX in the 4th quarter valued at $1,956,000. State of New Jersey Common Pension Fund D lifted its stake in shares of MEDNAX by 30.7% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 108,777 shares of the company’s stock valued at $2,960,000 after purchasing an additional 25,565 shares during the last quarter. AlphaCrest Capital Management LLC lifted its stake in shares of MEDNAX by 200.2% in the 3rd quarter. AlphaCrest Capital Management LLC now owns 31,130 shares of the company’s stock valued at $885,000 after purchasing an additional 20,761 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in shares of MEDNAX by 147.9% in the 3rd quarter. Millennium Management LLC now owns 170,144 shares of the company’s stock valued at $4,837,000 after purchasing an additional 101,516 shares during the last quarter. 95.68% of the stock is currently owned by institutional investors.

Shares of MEDNAX stock traded down $0.19 on Friday, reaching $18.71. The company’s stock had a trading volume of 1,225,968 shares, compared to its average volume of 597,542. The company has a market capitalization of $1.63 billion, a P/E ratio of 17.49, a PEG ratio of 1.17 and a beta of 2.05. MEDNAX has a 52-week low of $18.36 and a 52-week high of $35.67. The stock has a 50-day moving average price of $22.75 and a 200-day moving average price of $24.87. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.92.

About MEDNAX (Get Rating)

MEDNAX, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.

Further Reading

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.